小儿推拿治疗功能性消化不良:随机对照试验的系统评价与Meta分析
结果显示推拿可显著提高总有效率、降低消化不良症状评分、缩短腹胀腹痛嗳气厌食缓解时间并降低复发率,且未报告不良事件,但原始研究方法学质量存在缺陷。
要点
- 推拿联合常规治疗较单用常规治疗显著提高总有效率(RR=1.16)。
- 推拿可降低消化不良症状总评分并缩短腹胀、腹痛、嗳气、厌食缓解时间。
- 推拿组未报告不良事件,但原始研究方法学质量需改进。
核心结论
- 推拿可有效且安全地改善功能性消化不良患儿的临床症状,但需解决原始研究的方法学缺陷以获得更可靠证据。
研究设计与样本
- 两名评价员独立筛选文献并提取数据,采用Cochrane偏倚风险工具评估方法学质量,使用Review Manager软件进行Meta分析。
主要发现
- 推拿单独或联合常规治疗较单用常规治疗显著提高有效率(RR=1.16,95%CI [1.11, 1.21],p<0.00001)。
- 联合推拿组消化不良症状总评分显著降低(SMD=-1.18,95%CI [-1.46, -0.91],p<0.00001)。
- 联合推拿组腹胀缓解时间(MD=-2.08,95%CI [-2.35, -1.81])、腹痛缓解时间(MD=-1.54,95%CI [-1.92, -1.17])、嗳气缓解时间(MD=-1.11,95%CI [-1.44, -0.77])和厌食缓解时间(MD=-1.37,95%CI [-1.67, -1.07])均显著缩短,p均<0.00001。
- 治疗后复发率显著降低(RR=0.32,95%CI [0.14, 0.72],p=0.006)。
- 血清胃动素水平(MD=22.93,95%CI [13.56, 32.30],p<0.00001)和尿D-木糖排泄(MD=3.11,95%CI [0.31, 5.92],p=0.03)均升高;联合推拿组与常规治疗组在四项个体消化不良症状及神经肽Y水平上无显著差异;推拿组未报告不良事件。
临床怎么用
- 可考虑将推拿作为功能性消化不良患儿的辅助治疗,与常规治疗联合使用以改善症状和降低复发。
- 应用时需关注原始研究的方法学局限性,结合临床具体情况个体化决策。
局限性
- 原始随机对照试验存在已识别的方法学缺陷,可能影响证据的稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Functional dyspepsia (FD) is the most prevalent pediatric gastrointestinal disorder, imposing a significant burden on healthcare services and often persisting into adulthood. Tuina, a traditional manual therapy, is frequently employed in the treatment of FD. This study aimed to systematically evaluate the efficacy and safety of Tuina in treating FD in children. METHODS: A comprehensive search of 11 databases was conducted for randomized controlled trials (RCTs) published up to June 2022. Two independent reviewers screened the literature, extracted data, assessed the methodological quality of the RCTs using the Cochrane risk-of-bias tool, and performed meta-analysis using Review Manager software to quantify Tuina's efficacy. RESULTS: The review covered ten RCTs with 1336 children. Tuina, alone or with conventional therapy (CT), significantly improved efficacy rates over CT alone (relative risk (RR) = 1.16, 95 % confidence interval (CI) [1.11, 1.21], p < 0.00001). The combined Tuina group demonstrated significantly lower overall dyspeptic symptom scores (standard mean difference (SMD) = -1.18, 95 % CI [-1.46, -0.91], p < 0.00001) and shorter times to resolution of primary symptoms, including abdominal distension (mean difference (MD) = -2.08, 95 % CI [-2.35, -1.81], p < 0.00001), abdominal pain (MD = -1.54, 95 % CI [-1.92, -1.17], p < 0.00001), belching (MD = -1.11, 95 % CI [-1.44, -0.77], p < 0.00001), and anorexia (MD = -1.37, 95 % CI [-1.67, -1.07], p < 0.00001). Additionally, the recurrence rate following treatment was significantly lower (RR = 0.32, 95 % CI [0.14, 0.72], p = 0.006). The levels of serum motilin (MD = 22.93, 95 % CI [13.56, 32.30], p < 0.00001) and urinary excretion of D-xylose (MD = 3.11, 95 % CI [0.31, 5.92], p = 0.03) were also elevated. There were no significant differences between the combined Tuina and CT groups regarding the four individual dyspeptic symptoms or neuropeptide Y levels. No adverse events were reported in the Tuina group. CONCLUSION: This systematic review collectively suggest that Tuina effectively and safely improves clinical symptoms in children with FD. However, addressing identified methodological weaknesses is crucial for future studies to ensure robust evidence.
引用
- Ha NY, Keum CY, Kim J, et al. Pediatric Tuina for the treatment of functional dyspepsia: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2024. PMID: 39662848. doi:10.1016/j.ctim.2024.103117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。